The kit is designed to detect polymorphisms associated with drug resistance to second-line chemotherapy drugs (aminoglycosides and fluoroquinolones) and their analogues. The result of the assay makes it possible to choose the appropriate therapy for patients with a confirmed diagnosis of pulmonary and extrapulmonary tuberculosis.